Advertisement

Möglichkeiten des Androgenentzugs und der totalen Blockade

  • F. Neumann
  • M. F. El Etreby
  • U.-F. Habenicht
  • A. Radlmaier
  • K. Bormacher

Zusammenfassung

Die Prostata gehört zu den klassischen Zielorganen für Androgene. Die strukturelle Integrität und sekretorische Aktivität zumindest in der normalen Prostata sind deshalb androgenabhängig. Androgenmangel oder Androgenentzug führt zur Atrophie und zum Verlust der sekretorischen Aktivität.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abdalla HI (1985) Pathophysiology of hot flushes. Review 40 /6: 338–343Google Scholar
  2. Ahmed SR, Grant J, Shalet SM, Howell A, Chowdhury SD, Weatherson T, Blacklock NJ (1985) Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. Brit Med J 290 /6463: 185–187CrossRefGoogle Scholar
  3. Allen JM, Kerle DJ, Ware H, Doble A, Williams G, Bloom SR (1983) Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. Brit Med J 287: 1766CrossRefGoogle Scholar
  4. Bates GW (1981) On the nature of the hot flash. Clin Obstet Gynecol 24/2:231–240PubMedCrossRefGoogle Scholar
  5. Gibod L, Laudat MH, Dugue MA, Steg A (1986) Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol 12: 400–402Google Scholar
  6. Boumier P, Koeger A-C, Camus JP (1985) Aggravation dramatique d’un cancer prostatique au début d’un traitement par un agoniste de la gonadoréline. Presse méd 14 /21: 1200–1201PubMedGoogle Scholar
  7. Bridge RW, Scott WW (1964) A new antiandrogen, SH-714. Invest Urol 2: 99PubMedGoogle Scholar
  8. Cabot AT (1896) The question of castration for enlarged prostate. Ann Surg 24: 265PubMedCrossRefGoogle Scholar
  9. Casper RF, Yen SSC (1985) Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol 22: 293–312CrossRefGoogle Scholar
  10. Claes H, Vanderbussche L, Vereecken RL (1986) Treatment of advanced carcinoma of the prostate by LHRH agonists. 7th Congr Europ Assoc Urol, Budapest/Hungary, June 26–28Google Scholar
  11. Donn F, Becker H, Kuhlencordt R, Klosterhalfen H (1986) Hat das Antiandrogen Cyproteronacetat (Androcur) androgene Wirkung? XXXVIII Kongr Dtsch Gesell Urol, WürzburgGoogle Scholar
  12. Eaton AC, McGuire N (1983) Cyproterone acetate in treatment of post-orchidectomy hot flushes. Lancet 8363: 1336–1337CrossRefGoogle Scholar
  13. Frisch A von (1906) In: Frisch A von, Zuckerkandl G (Hrsg) Handbuch der Urologie, Alfred Holder, WienGoogle Scholar
  14. Frödin T, Alund G, Varenhorst E (1985) Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate 7: 203–208PubMedCrossRefGoogle Scholar
  15. Gingell JC (1984) Does orchidectomy cause excessive sweating? Brit Med J 288: 709Google Scholar
  16. Goldenberg L, Coppin C, Bruchovsky N, Brown E, Rennie PS, McLoughlin M (1985) Cyproterone acetate plus mini-dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer. Clin Invest Med 8A: 164, Abstract R-762Google Scholar
  17. Habenicht U-F, Düsterberg B, El Etreby FM, Neumann F (1985) Hat Cyproteronacetat eine androgen-agonistische Wirkung? 29. Symp Dtsch Ges Endokrinol, GöttingenGoogle Scholar
  18. Habenicht U-F, Witthaus E, Neumann F (1986) Antiandrogene und LHRH-Agonisten: Endokrinologie in der Initialphase ihrer Anwendung. Akt Urol 17: 10–16CrossRefGoogle Scholar
  19. Horn HJ (1974) Administration of antiandrogens in hypersexuality and sexual deviations. In: Eichler O, Farah A, Herken H, Welch AD (eds) Androgens II and antiandrogens, Springer, Berlin Heidelberg New York, chapt VIII, pp 543–562Google Scholar
  20. Huggins C (1945) The physiology of the prostate gland. Physiol Rev 25: 117Google Scholar
  21. Huggins C, Clark PJ (1940) Quantitative studies of prostatic secretion. II. The effect of castration and estrogen injection on the normal and on the hyperplastic prostate glands of dogs. J Exp Med 72: 747PubMedCrossRefGoogle Scholar
  22. Huggins C, Hodges CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on the normal and on the hyperplastic prostate glands of dogs. Cancer Res 1: 293Google Scholar
  23. Huggins C, Rüssel PS (1946) Quantiative effects of hypophysectomy on testis and prostate of dogs. Endocrinology 39: 1CrossRefGoogle Scholar
  24. Huggins C, Scott WW, Hodges CV ( 1941 a) Studies on prostatic cancer. III. The effects of fever, of desoxy-corticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 46: 997Google Scholar
  25. Huggins C, Stevens RE jr, Hodges CV ( 1941 a) Studies on prostatic cancer. II. Effects of castration on advanced carinoma of prostate gland. Arch Surg 43: 209CrossRefGoogle Scholar
  26. Jacobi GH, Tunn U, Senge Th (1982) Clinical experience with cyproterone acetate for palliation of inoperable prostate cancer. In: Jacobi GH, Hohenfellner R (eds) Prostate Cancer, Williams & Wilkins, Baltimore/London, vol. 3, pp 305–319Google Scholar
  27. Kahan A, Delrieu F, Amor B, Chiché R, Steg A (1984) Disease flare induced by D-Trp-6-LHRH analogue in patients with metastatic prostatic cancer. Lancet 8383: 971–972CrossRefGoogle Scholar
  28. Klign JGM, de Voogt HJ, Schröder FH, de Jong FH (1985) Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma. Lancet 8453: 493Google Scholar
  29. Knuth UA, Hano R, Nieschlag E (1984) Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metabol (Phil) 59: 963–969CrossRefGoogle Scholar
  30. Labrie F, Dupont A, Bélanger A, Giguère M, Lacoursière Y, Edmond J, Monfette G, Bergeron V (1985) Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Ster Biochem 23 (5B): 833–841CrossRefGoogle Scholar
  31. Moon TD (1985) Cyproterone acetate for treatment of hot flashes after orchiectomy. J Urol 134: 155–156PubMedGoogle Scholar
  32. Neumann F (1987, nicht publizierte Daten)Google Scholar
  33. Neumann F, Jacobi GH (1982) Antiandrogens in tumour therapy. In: Furr BJA (ed) Clinics in oncology. WB Saunders, London Philadelphia, vol 1, chapt 3, pp 41–64Google Scholar
  34. Neumann F, Schenck B (1980) Antiandrogens: Basic concepts and clinical trials. In: Cunningham GR, Schill W-B, Hafez ESE (eds) Regulation of male fertility. Martinus Nijhoff, The Hague, Boston London, vol 5, pp 93–104Google Scholar
  35. Neumann F, Gräf K-J, Hsan SH, Schenck B, Steinbeck H (1977) Central actions of antiandrogens. In: Martini L, Motta M (eds) Androgens and antiandrogens. Raven, New York, pp 163–177Google Scholar
  36. Neumann F, Schleusener A, Albring M (1979) Pharmakologie der Antiandrogene. In: Hammerstein J, Lachnit-Fixson U, Neumann F, Plewig G (Hrsg) Androgenisierungserscheinungen bei der Frau — Akne, Seborrhö, androgenetische Alopezie und Hirsutismus. Excerpta Medica, Amsterdam Oxford Princeton, S 149–194Google Scholar
  37. Neumann F, Hümpel M, Senge Th, Schenck B, Tunn U (1982) Cyproterone acetate — biochemical and biological basis for treatment of prostatic cancer. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer. Williams & Wilkins, Baltimore London, vol 3, pp 269–303Google Scholar
  38. Neumann F, Habenicht U-F, Schacher A (1984) Antiandrogens and target cell response — different in vivo effects of cyproterone acetate, flutamide and cyproterone. In: McKerns KW, Aakvaag A, Hansson V (eds) Regulation of Target Cell Responsiveness. Plenum, New York, vol II, pp 489–527Google Scholar
  39. Parmar H, Lithman SL, Allen L, Phillips RH, Edwards L, Schally AV (1985) Randomised controlled study of orchidectomy vs. long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 8466:1201–1205 Persönliche MitteilungGoogle Scholar
  40. Poyet P, Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 42: 283–288PubMedCrossRefGoogle Scholar
  41. Raynaud JP, Bonne C, Moguilewsky M, Lefebvre FA, Bélanger A, Labrie F (1984) The pure antiandrogen RU 23908 (Androcur), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review. Prostate 5: 299Google Scholar
  42. Schacher A, El Etreby MF, Neumann F (1984) Einfluß von Cyproteronacetat, Flutamid und Spironolacton auf die Achse Hypothalamus-Hypophyse-Hoden bei Ratte. Akt Urol 15 /4: 218–225CrossRefGoogle Scholar
  43. Steinfeld AD, Reinhardt Ch (1980) Male climacteric after orchiectomy in patient with prostatic cancer. Urology XVI /6: 620–622CrossRefGoogle Scholar
  44. Sugimura Y, Cunha GR, Bigsby RM (1986) Androgenic induction of DNA synthesis in prostatic glands induced in the urothelium of testicular feminized ( Tfm/Y) mice. Prostate 9: 217–225Google Scholar
  45. Svensson M, Varenhorst E, Kagedal B (1986) Initial administration of cyproterone acetate to prevent the rise of testosterone concentration during treatment with an LHRH agonist in prostatic cancer. Anticancer Res 6 /3: 379Google Scholar
  46. Trachtenberg J (1984) Ketoconazole therapy in advanced prostatic cancer. J Urol 132: 61–63PubMedGoogle Scholar
  47. Tunn U, Senge Th, Schenck B, Neumann F (1979) Biochemical and histological studies on prostates in castrated dogs after treatment with androstanediol, oestradiol and cyproterone acetate. Acta Endocrinol (Copenh) 91: 373–384Google Scholar
  48. Tunn U, Senge Th, Schenck B, Neumann F (1980) Effects of cyproterone acetate on experimentally induced canine prostatic hyperplasia. A morphological and histochemical study. Urol Internat 35: 125–140CrossRefGoogle Scholar
  49. Urwin GH, Williams JL, Kanis JA (1986) Antiandrogens attenuate testosterone ‘flare’ following Zoladex depot LHRH analogue in patients with prostatic cancer. 7th Congr Europ Assoc Urol (eau), Budapest/HungaryGoogle Scholar
  50. White JW (1895) The results of double castration in hypertrophy of the prostate. Trans Am Surg Assoc 22: 103Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • F. Neumann
    • 1
  • M. F. El Etreby
    • 2
  • U.-F. Habenicht
    • 2
  • A. Radlmaier
    • 1
  • K. Bormacher
    • 1
  1. 1.Clinical ResearchGermany
  2. 2.Institute of Pharmacology, Experimental Andrology and OncologyGermany

Personalised recommendations